English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The expression of microRNA‑335 (miR‑335) has been demonstrated to be downregulated in numerous types of cancer. Thus far, no previous studies have investigated the miR‑335 expression in bladder cancer. In the present study, the expression and effects of miR‑335 were assessed in bladder cancer. The results of the present study provided, to the best of our knowledge, the first evidence that miR‑335 is downregulated in the tumor tissue of patients with bladder cancer. Following transfection of miR‑335, MTT, cell migration and invasion, luciferase and western blot assays were conducted in bladder cancer cell lines. The results demonstrated that miR‑335 inhibited cell proliferation, migration and invasion in T24 and EJ cells. In addition, the results suggested that miR‑335 directly targets Rho‑associated protein kinase 1 (ROCK1) in bladder cancer. The present study provided a novel therapeutic target, the miR‑335/ROCK1 axis in bladder cancer. The suggested approach will be beneficial in developing an effective treatment against bladder cancer.

MicroRNA-335 is downregulated in bladder cancer and inhibits cell growth, migration and invasion via targeting ROCK1